Phase 1 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to read and sign a consent form agreeing to take part in the study.
- Adults aged 18 or older (male or female).
- People who have had their cancer confirmed through a tissue sample as squamous cell carcinoma of the head and neck.
- People for whom surgery to remove the cancer is already planned as part of their standard treatment.
- People who are generally well enough to function independently or with only minimal limitations in daily activities (this is measured using a standard scale called ECOG — confirm with trial site).
- People whose blood counts, kidney function, and liver function are considered acceptable for surgery, based on routine pre-surgery tests.
- Women who could potentially become pregnant must have a negative pregnancy test within 14 days before starting the study treatment, and must agree to use effective contraception or remain abstinent during treatment and for 5 months after the last dose of the study drug panitumumab.
- Men must agree to use a condom or remain abstinent during treatment and for 5 months after the last dose of the study drug, and must agree not to donate sperm during this time.
Who may not be able to join:
- People who are not considered suitable for standard surgical removal of their cancer.
- People who have previously had an infusion reaction or allergic reaction to the drug panitumumab.
- People with a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-induced lung inflammation, or idiopathic pneumonitis — or people who show signs of active lung inflammation on a pre-study CT scan (note: a history of radiation-related lung scarring is generally permitted — confirm with trial site).
- People with currently active tuberculosis.
- People who have had a significant heart or stroke-related event within the 3 months before starting the study treatment, or who have an unstable irregular heartbeat or unstable chest pain condition.
- People with a history of severe allergic (anaphylactic) reactions to certain types of antibody-based medicines.
- People currently taking certain heart rhythm medications, specifically Class IA drugs (such as quinidine or procainamide) or Class III drugs (such as dofetilide, amiodarone, or sotalol), or who have taken these within 30 days before the study.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study or within 5 months after the last dose of the study drug.
- People with low magnesium or phosphorus levels that are causing symptoms and cannot be corrected with standard supplementation.
- People who show a specific type of irregular heart electrical activity (called QTcF prolongation) on a pre-study heart trace (ECG).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Eben L Rosenthal, MD, Vanderbilt University/Ingram Cancer Center
Phone: 615-936-2807
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine maximum tumor concentrating dose (MTC) of panitumumab in HNSCC.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.